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Abstract
Background: Ergogenic aides are widely used by fitness enthusiasts and athletes to increase performance. Alpha
glycerylphosphorylcholine (A-GPC) has demonstrated some initial promise in changing explosive performance. The
purpose of the present investigation was to determine if 6 days of supplementation with A-GPC would augment
isometric force production compared to a placebo.
Methods: Thirteen college-aged males (Means ± SD; Age: 21.9 ± 2.2 years, Height: 180.3 ± 7.7 cm, Weight: 87.6 ±
15.6 kg; VO2 max: 40.08 ± 7.23 ml O2*Kg
−1*min−1, Body Fat: 17.5 ± 4.6 %) gave written informed consent to
participate in the study. The study was a double blind, placebo controlled, cross-over design. The participants
reported to the lab for an initial visit where they were familiarized with the isometric mid thigh pull in a custom
squat cage on a force platform and upper body isometric test against a high frequency load cell, and baseline
measurements were taken for both. The participant then consumed either 600 mg per day of A-GPC or placebo
and at the end of 6 days performed isometric mid thigh pulls and an upper body isometric test. A one-week
washout period was used before the participants’ baseline was re-measured and crossed over to the other
treatment.
Results: The A-GPC treatment resulted in significantly greater isometric mid thigh pull peak force change from
baseline (t = 1.76, p = 0.044) compared with placebo (A-GPC: 98.8. ± 236.9 N vs Placebo: −39.0 ± 170.9 N). For
the upper body test the A-GPC treatment trended towards greater change from baseline force production
(A-GPC: 50.9 ± 167.2 N Placebo: −14.9 ± 114.9 N) but failed to obtain statistical significance (t = 1.16, p = 0.127).
Conclusions: A-GPC is effective at increasing lower body force production after 6 days of supplementation. Sport
performance coaches can consider adding A-GPC to the diet of speed and power athletes to enhance muscle
performance.
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Background
Performance in sport is often determined by moments
of extreme force production and power output [1].
While much of this can be attributed to muscular
strength [2, 3], some adaptations to training can be
neural in nature [4]. A study by Pensini, Martin and
Maffiuletti [5] demonstrated that increases in torque as-
sociated with 4 weeks of eccentric exercise were likely
the result of central (or neural) adaptation. Based upon
current knowledge it appears that both central and per-
ipheral adaptations are necessary to enhance perform-
ance in athletes. Therefore, it is important to study
nutritional interventions that have the potential to aug-
ment either potential site of adaptation.
α Glycerylphosphorylcholine (A-GPC) is a substance
that could potentially augment human performance by
facilitiating neuro-muscular interaction. A-GPC has been
shown to augment acetylcholine levels in neurons in rat
CNS [6], and has been shown to maintain reaction time in
humans following exhaustive exercise [7]. Additionally A-
GPC is generally considered safe for consumption in
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moderate to high doses [8, 9]. Ingested A-GPC is con-
verted to phosphatidylcholine, a source of choline [10].
Dietary choline levels are linked to the rate of biosynthesis
of acetylcholine [11]. Given that cholinergic nerves trigger
muscle contraction, and that choline availability is linked
to acetylcholine synthesis substances that could augment
choline availability might have the potential to influence
muscular performance. To date some work has been done
examining the ability of phospholipids to restore choline
levels after exercise, but there is a dearth of information
regarding the ability of compounds like A-GPC to acutely
enhance performance [11]. The purpose of this study was
to examine the effects of 6 days of supplementation with
A-GPC on measures of isometric force production in the
upper and lower body.
Methods
The Institutional Review Board at the University of
Louisiana at Lafayette reviewed the present investigation
for ethics. The study was a double-blind, placebo-
controlled crossover with a 1-week washout period that
included 13 healthy, college-aged males (Means ± SD;
Age: 21.9 ± 2.2 years, Height: 180.3 ± 7.7 cm, Weight:
87.6 ± 15.6 kg; VO2 max: 40.08 ± 7.23 ml O2*Kg
−1*min−1,
Body Fat: 17.5 ± 4.6 %). Subjects reported to the lab and
give informed consent, which included consent to publish,
prior to baseline assessments which included height and
weight, an assessment of maximum aerobic capacity via a
COSMED CPET system (COSMED, Rome ITL) with inte-
grated electronically braked cycle ergometer as outlined in
previous studies [12], and body fat percentage via air dis-
placement plethysmography (Bod Pod Gold Standard Sys-
tem, COSMED Rome, ITL) . The following week trial one
(random order: either placebo or 600 mg of A-GPC)
began. For the trials baseline performance testing was
done and they were given an initial dose (placebo or A-
GPC) while in the lab, 1 h later the performance testing
(isometric mid thigh pull, upperbody isometric test) was
repeated. The subjects were then given 6 days of add-
itional pre-packaged supplement to take (morning and
evening). The subjects reported back on day 6 of this
period to repeat performance testing after the final dose of
supplement. After a 1-week washout period, the subjects
repeated the trial with the other treatment. (see Fig. 1).
Treatments
The treatments consisted of 600 mg daily of A-GPC
(AlphaSize®, ChemiNutra, Austin, TX) or a placebo. Both
Fig 1 Flowchart of Experimental Procedures
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treatments were administered in the same capsules (gel
caps) and were the same color (white). The A-GPC
capsules were supplied with a certificate of analysis
from a third party lab confirming the amount of active
ingredient. The placebo capsule consisted of microcrys-
talline cellulose and magnesium stearate (Nature’s Sup-
plements, Carlsbad, CA USA). Both the participant and
researcher were unaware of the identity of either treat-
ment until the end of the study.
The participants were instructed to take doses in the
morning and evening that would deliver a total of
600 mg of A-GPC per day and were given the pills in a
non-distinct plastic bottle marked only with a code. The
participants returned the bottles at the end of the study.
The participants reported 100 % compliance with taking
the required doses.
Isometric mid thigh pull (IMTP)
The isometric mid-thigh pull test (IMTP) is a well-
validated strength measure [13]. Testing was conducted
in a customized power rack (Rogue Fitness, Columbus,
USA) that is secured to a concrete laboratory floor sur-
rounding a AMTI Force Plate (Advanced Materials
Technologies Inc., Watertown USA). The power rack al-
lows for small incremental adjustments in height for a
steel bar that is secured via two large tubular steel
members.
The participant was instructed to stand with the feet
shoulder width apart above the force plate. The height
of the bar was adjusted so that the participant was in a
position where the torso was upright (assessed via a con-
tractors box level), the knees achieved between 120–130°
of flexion (measured via a goniometer) and the arms
were straight while holding the bar. The participants
were told to "drive straight up" and to pull as hard as
they could against the chain until the force began to no-
ticeably decline. The peak force was assessed at a sam-
pling rate of 2000 Hz using an AMTI Force Plate.
Subjects were familiarized with the IMTP during the ini-
tial lab visit. Measurements were taken in triplicate with
a five-minute rest.
Upper body isometric test (UBIST)
The participants were positioned on three elevated plat-
forms with the chest directly suspended over a load cell
anchored into the concrete floor of the lab (iLoad Pro,
Loadstar Sensors, Fremont CA). The load cell had a cap-
acity of greater than 5000 N and a listed accuracy of
0.25 % for the full scale of measurement. The partici-
pants were placed in a push-up style position, with the
hands at 150 % of biacromial width, and the elbows at
90° of extension (measured via a goniometer). A thick,
non-elastic strap was run over one shoulder and under
the opposite shoulder and connected with metal rings to
a chain that was tethered to the load cell.
The participants were instructed to keep their backs
flat, and push with their hands maximally until told to
stop by the researcher. Prior to data capture the load cell
was tared to ensure the weight of the load cell and ap-
paratus were accounted for. The researcher started data
collection and verbally instructed the participant to
“push as hard as possible”. The participants were ver-
bally encouraged during data collection, which was ter-
minated when the force production declined by 50 N
from the peak value registered. The load cell was set to
capture data at maximum rate (150Hz) and the data was
exported and analyzed in JMP 11.0 (SAS Institute Inc,
Cary NC). Peak force values were isolated from the data
and used for subsequent analysis. The test was per-
formed three times with 5 min rest between assess-
ments. The validity and reliability of this test have been
reported in the literature [14].
Statistical analysis
Reliability was assessed for the isometric tests via Intra
Class Correlation Coefficients (ICC). Repeated measures
Ancovas were used to examine acute (baseline and 1 h
post) and chronic (baseline and day 6) changes in per-
formance between treatments. Order of administration
(Placebo first, A-GPC first) was entered into the model
as a covariate. G*Power software [15] was used to deter-
mine effect size (Cohen’s d), all other analyses were
performed using a modern statistical software package
(JMP, version 11.0 SAS Institute Inc., Cary, NC). Magni-
tude based inferences were calculated to assist with
interpretation of results [16]. The use of magnitude
based inference is an attempt to expand the interpret-
ation of findings to include harmful, trivial and beneficial
as interpretations, rather than just significant, non-
significant [17]. This interpretations in not without
controversy [18], as such the authors have chosen to in-
clude it alongside a more traditional statistical approach.
Results
Reliability of isometric tests
The isometric tests demonstrated reliability when the
triplicate measurements were examined via ICC
(range: 0.969–0.984). Measurements were not different
at any time points (p > 0.05). Therefore in subsequent
analysis the peak value from the set of three measures
was used.
Treatment effects—acute
Repeated measures Anova did not reveal any main ef-
fects (F = 0.003, p = 0.9584) nor interaction effects of
treatment*time (F = 0.114, p = 0.738) for IMTP perform-
ance 1 h after the initial dose of A-GPC or Placebo.
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Similar results were revealed when UBIST performance
was analyzed.
Treatment effects—chronic
Repeated measures Anova revealed a significant inter-
action effect for treatment (A-GPC vs Placebo) by time
(baseline, day 6) for IMTP peak performance (F = 3.12,
p = 0.04; change from baseline A-GPC: 98.8. ± 236.9 N
vs Placebo: −39.0 ± 170.9 N, ES = 0.961). See Fig. 2.
For the upper body test the A-GPC treatment trended
towards greater change from baseline force production
(A-GPC: 50.9 ± 167.2 N Placebo: −14.9 ± 114.9 N) but
the interaction effect of treatment by time failed to
obtain statistical significance (F = 1.36, p = 0.127).
However, this data (see Fig. 3) demonstrated a large
effect size (ES = 0.714). This suggests that the variabil-
ity of the subject’s upper body strength limited the
statistical power, however, it if likely that a real effect
exists in this data. Magnitude based inferences suggest
that the A-GPC was 68.3 % likely beneficial for in-
creasing upper body isometric force and 86.5 % likely
beneficial for increasing lower body isometric force
production.
Discussion
The results of this study support the use of A-GPC to
enhance strength, particularly in the lower body after
6 days of administration of a 600 mg dose. The literature
does not contain controlled experimental data regarding
the effects of A-GPC on aspects of human performance
directly related to isometric strength, and thus this study
represents a first step in the evaluation of this product
for such use. The literature does contain some evidence
that choline itself is important to consider in regard to
endurance performance [19, 20]. The current literature
does contain some information about A-GPC and per-
formance measurements. Jagim et al. [21] reported that
a multi-ingredient supplement that contained A-GPC
enhanced mean power during a maximal effort sprint
test on a non-motorized treadmill but did not produce
any changes in counter movement jumping performance
peak or mean power. Parker et al. [22] reported acute
supplementation with 200 mg or 400 mg of A-GPC did
not statistically enhance performance, thought the authors
did note a non-significant trend in vertical jump peak
power. Acute supplementation with 600 mg of A-GPC
has been shown to augment bench press power in a small
sample of men with 2 years of training experience [23].
Fig 2 Mean change in Isometric Mid Thigh Pull Peak force after 6 days of supplementation with A-GPC. Error bars represent +/− 1 SEM
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This study is similar in finding to the present investigation
in dose of A-GPC administered (600 mg) and suggests en-
hancements in performance. These previously reported
studies on A-GPC vary greatly in design, measurements
and administrations. The lack of consistency of doses
(200–600 mg) and time of administration (30–90 min
prior to activity) may explain the lack of consistent find-
ings. Given the present evidence in the literature, further
studies will be needed to confirm the results reported
from this experiment, the data represent a promising start
and suggest alternative uses for A-GPC.
The potential mechanism by which A-GPC could con-
fer enhanced strength and power performance involves
increased bio-available choline, which may result in aug-
mented acetylcholine synthesis in neurons. A-GPC has
been shown to augment acetylcholine levels in CNS
neurons [6]. Evidence suggests that when administered
intramuscularly A-GPC can increase plasma choline
levels [24]. A-GPC has also been shown to increase
growth hormone secretion though the action of acetyl-
choline stimulated catecholamine release [25]. This in-
crease in cholinergic tone and associated increased
growth hormone release was also reported in old and
young subjects after administration of growth hormone
releasing hormone in conjunction with A-GPC [26]. In
the present investigation it is unlikely a moderate in-
crease in growth hormone over the course of 7 days
would have impacted maximum strength although this
evidence suggests that longer chronic studies of A-GPC
may be warranted as chronic elevations in growth hor-
mone could potentially further augment performance.
While the present study presents positive preliminary
findings for A-GPC augmenting strength, it is not with-
out limitation. The present investigation is limited by
sample size. The study will need to be replicated with
larger study populations and alternative measures of hu-
man performance, likely those that have the capacity to
measure power not just peak force. Additionally, differ-
ent does of A-GPC need to be explored to determine
any potential dose-response, or lower limit for meaning-
ful effect. We suggest that in vitro studies may also be
warranted to demonstrate that A-GPC has the potential
to augment neurotransmitter levels in motor neurons.
These studies can help to clarify the timing of A-GPC
administration, which may in turn result in studies with
a more targeted and informed dosing scheme.
Conclusions
The results of the study suggest that A-GPC is effective
at increasing lower body force production after 6 days of
supplementation. A similar trend was noted in upper
body isometric strength, however; this failed to attain
statistical significance. Given that in many sports it is
understood that a very small change in performance,
often times less than 2 %, can significantly affect out-
comes it is important to note that the 6 days of A-GPC
resulted in greater than a 3 % increase in lower body iso-
metric strength. Sport performance coaches can consider
Fig 3 Mean change in Upperbody Isometric Test force after 6 days of supplementation with A-GPC. Error bars represent +/− 1 SEM
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adding A-GPC to the diet of speed and power athletes
to potentially enhance muscle performance.
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